Celltrion Decides to Expire European Phase 3 Clinical Trial Plan

Celltrion (068270) announced via a public disclosure on June 18, 2026, that the clinical trial plan for CT-P13 SC's European Phase 3 trial has expired. This follows a strategic shift in clinical development, with the company deciding not to submit a new Part 2 trial plan. The trial was a global Phase 3 study evaluating the efficacy and safety of CT-P13 subcutaneous injection in pediatric patients with moderate-to-severe active ulcerative colitis. The regulatory authority was the European Medicines Agency (EMA), which approved the trial on June 17, 2024. Celltrion plans to finalize future schedules after regulatory discussions on trial design. As of 10:10 PM on June 18, 2026, Celltrion's stock closed at 173,600 won, down 1,000 won from the previous day. Recent financial figures show total assets of 22.3349 trillion won, total liabilities of 4.9824 trillion won, total capital of 17.3525 trillion won, revenue of 4.1625 trillion won, operating income of 1.1685 trillion won, and net income of 131.5 billion won (on a consolidated basis, as Celltrion is a December-end settlement company). The company, listed on the KOSPI market since February 27, 1991, is a biopharmaceutical firm.